ApoC-III gene polymorphisms and risk of coronary artery disease

This publication has 35 references indexed in Scilit:

• VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial
  Circulation, 2000
• The trouble with triglycerides.
  Archives of internal medicine (1960), 2000
• Triglyceride-Rich Lipoprotein Remnant Particles and Risk of Atherosclerosis
  Circulation, 1999
• Role of ApoCs in Lipoprotein Metabolism
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1999
• Apolipoprotein C-lll gene variation and dyslipidaemia
  Current Opinion in Lipidology, 1997
• Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS)
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1996
• Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
  Circulation, 1994
• An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms.
  Proceedings of the National Academy of Sciences, 1993
• Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.
  Circulation, 1990
• Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
  Journal of Clinical Investigation, 1986